publication venue for
- Validity of the Activities-specific Balance Confidence Scale in individuals with chronic obstructive pulmonary disease. 16:689-696. 2022
- Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. 15:1003-1011. 2021
- Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update. 13:1139-1146. 2019
- The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. 13:139-152. 2019
- Adherence and outcomes: a systematic review of palivizumab utilization. 12:27-42. 2018
- The use of cellular and molecular biomarkers to manage COPD exacerbations. 11:1-9. 2017
- Riociguat for the treatment of pulmonary hypertension. 9:679-695. 2015
- Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. 9:779-799. 2015
- Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma. 9:135-142. 2015
- The potential to predict the course of childhood asthma. 8:137-141. 2014
- New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research. 7:465-478. 2013
- Update on exhaled nitric oxide in pulmonary disease. 6:105-115. 2012
- Montelukast in childhood asthma: what is the evidence for its use?. 5:17-25. 2011
- Pulmonary mucosal dendritic cells in T-cell activation: implications for TB therapy. 5:75-85. 2011
- Roflumilast: systemic therapy for chronic obstructive pulmonary disease. 2:539-549. 2008